Minodronate

Minodronic acid

Minodronic acid

Chemical compound

Not to be confused with mildronate or medronate.

Minodronic acid is a third-generation bisphosphonate drug. It is approved for use in Japan for the treatment of osteoporosis.[1] Its mechanism of action involves inhibition of farnesyl pyrophosphate synthase activity.[2]

Quick Facts Names, Identifiers ...

References

  1. [1]
    Shridhar Hegde and Michelle Schmidt (2009). "To Market, To Market - 2009. 16. Minodronic acid". Annual Reports in Medicinal Chemistry. 45: 509–510. doi:10.1016/s0065-7743(10)45028-9.
  2. [2]
    Sorbera, L.A.; Castañer, J.; Leeson, P.A. (2002). "Minodronic Acid". Drugs of the Future. 27 (10): 935–941. doi:10.1358/dof.2002.027.10.701186.
Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Minodronate, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.